A Potent Chemotherapeutic Strategy With Eg5 Inhibitor Against Gemcitabine Resistant Bladder Cancer

PLoS ONE - United States
doi 10.1371/journal.pone.0144484
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

P63 Expression Correlates With Sensitivity to the Eg5 Inhibitor AZD4877 in Bladder Cancer Cells

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2012English

A Pharmacological Strategy Using Stemofoline for More Efficacious Chemotherapeutic Treatments Against Human Multidrug Resistant Leukemic Cells

Asian Pacific Journal of Cancer Prevention
2018English

Polycationic Calixarene PTX013, a Potent Cytotoxic Agent Against Tumors and Drug Resistant Cancer

Investigational New Drugs
OncologyPharmacology
2013English

Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells

Cancers
Cancer ResearchOncology
2019English

Establishment and Characterization of the Gemcitabine‑resistant Human Pancreatic Cancer Cell Line SW1990/gemcitabine

Oncology Letters
Cancer ResearchOncology
2019English

ACHN-490, a Neoglycoside With Potent in Vitro Activity Against Multidrug-Resistant Klebsiella Pneumoniae Isolates

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2009English

Aspirin Inhibits Proliferation of Gemcitabine-Resistant Human Pancreatic Cancer Cells and Augments Gemcitabine-Induced Cytotoxicity

Acta Pharmacologica Sinica
MedicinePharmacology
2009English

A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma

Oncotarget
Oncology
2014English

XPO1 Inhibition by Selinexor Induces Potent Cytotoxicity Against High Grade Bladder Malignancies

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy